Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Kylonova (Xiamen) Biopharma co., LTD.
204 participants
Oct 29, 2025
INTERVENTIONAL
Conditions
Summary
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administered subcutaneously
Locations(59)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07327840